| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/10/2011 | US20110034384 COMBINATION VEGFR2 THERAPY WITH mTOR INHIBITORS |
| 02/10/2011 | US20110034370 Bis-met histones |
| 02/10/2011 | US20110033546 Pure sustained dichroa ferbrifuga alkone formulation |
| 02/10/2011 | US20110033539 Compositions and methods for preparing and using same |
| 02/10/2011 | US20110033534 Controlled release tamsulosin hydrochloride tablets and a process of making them |
| 02/10/2011 | US20110033528 Stabilized picoplatin oral dosage form |
| 02/10/2011 | US20110033524 Treatment of tumors |
| 02/10/2011 | US20110033519 Device with Aromatase Inhibitor for the Treatment and Prevention of Uterine Fibroids and Method of Use |
| 02/10/2011 | US20110033485 Analogues of glycolipids useful as immunoadjuvants |
| 02/10/2011 | US20110033483 Single-chain multivalent binding proteins with effector function |
| 02/10/2011 | US20110033482 Her3 as a determinant for the prognosis of melanoma |
| 02/10/2011 | US20110033481 Prospective identification and characterization of breast cancer stem cells |
| 02/10/2011 | US20110033472 Tumor Endothelial Marker 5-alpha Molecules and Uses Thereof |
| 02/10/2011 | US20110033471 Methods and compositions for modulating tumor cell activity |
| 02/10/2011 | US20110033466 Human transcriptomes |
| 02/10/2011 | US20110033461 Combination Therapy for the Treatment of Cancer |
| 02/10/2011 | US20110033460 ANTI-ErbB2 ANTIBODIES |
| 02/10/2011 | US20110033458 Combinations comprising epothilones and pharmaceutical uses thereof |
| 02/10/2011 | US20110033457 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| 02/10/2011 | US20110033456 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| 02/10/2011 | US20110033455 Methods For Inhibiting The Binding Of Endosialin To Ligands |
| 02/10/2011 | US20110033453 Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members |
| 02/10/2011 | US20110033452 Anti-Glypican 3 Antibody Having Modified Sugar Chain |
| 02/10/2011 | US20110033449 Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
| 02/10/2011 | US20110033448 Inhibitors of LL-37 Mediated Immune Reactivity to Self Nucleic Acids |
| 02/10/2011 | US20110033445 Carbohydrate-containing pan cancer marker |
| 02/10/2011 | US20110033441 Pyrimidine derivatives for the treatment of abnormal cell growth |
| 02/10/2011 | US20110033435 Composition of activated CD4 cells |
| 02/10/2011 | US20110033425 Parvovirus Having a CPG-Enriched Genome Useful for Cancer Therapy |
| 02/10/2011 | US20110033424 Use of adenovirus and nucleic acids coding therefor |
| 02/10/2011 | US20110033421 Methods related to immunostimulatory nucleic acid-induced interferon |
| 02/10/2011 | US20110033420 Macrocyclic compounds as hepatitis c virus inhibitors |
| 02/10/2011 | US20110033419 Methods and Compositions for Treating Cancer |
| 02/10/2011 | US20110033415 Agent for differentiating hematopoietic stem cell into natural killer cell comprising yc-1 or il-2 1 and a method of differentiating hematopoietic stem cell into natural killer cell using the same |
| 02/10/2011 | US20110033386 Method of detecting bladder cancer |
| 02/10/2011 | US20110033384 Chimeric polypeptides and their use |
| 02/10/2011 | US20110033378 Cysteine Engineered Antibodies For Site-Specific Conjugation |
| 02/10/2011 | US20110033377 Assay to detect a gynecological condition |
| 02/10/2011 | US20110033376 Treatment of Melanoma |
| 02/10/2011 | CA2772280A1 Compositions and methods of preparing alloreactive cytotoxic t cells |
| 02/10/2011 | CA2770307A1 Compositions containing jarid1b inhibitors and methods for treating cancer |
| 02/10/2011 | CA2770282A1 Composition and methods of treating viral infections and viral induced tumors |
| 02/10/2011 | CA2770248A1 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives as c-met tyrosine kinase modulators |
| 02/10/2011 | CA2770195A1 Aminopyrazole derivative |
| 02/10/2011 | CA2770155A1 Novel azaheterocyclic compounds |
| 02/10/2011 | CA2770100A1 Methods of using c-met modulators |
| 02/10/2011 | CA2770092A1 Treatment of prostate cancer |
| 02/10/2011 | CA2770042A1 Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
| 02/10/2011 | CA2769882A1 Targeting of bone marrow neovasculature |
| 02/10/2011 | CA2768990A1 Broad spectrum erbb ligand binding molecules and methods for preparing and using them |
| 02/09/2011 | EP2281901A2 Anti-tumour pharmaceutical composition with angiogenesis inhibitors |
| 02/09/2011 | EP2281884A1 Mesothelioma-specific promoter and use thereof |
| 02/09/2011 | EP2281843A1 Antibodies that immunospecifically bind to blys |
| 02/09/2011 | EP2281842A1 Antibodies that immunospecifically bind to BLyS |
| 02/09/2011 | EP2281841A2 Biomarkers for pre-selection of patients for anti-IGF1R therapy |
| 02/09/2011 | EP2281822A1 New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them |
| 02/09/2011 | EP2281821A1 Process for producing crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole |
| 02/09/2011 | EP2281818A1 Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient |
| 02/09/2011 | EP2281578A2 Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer |
| 02/09/2011 | EP2281576A1 Active targeting type polymeric micelle carrying drug enclosed therein and medicinal composition |
| 02/09/2011 | EP2281575A1 Antibodies for treating cancer |
| 02/09/2011 | EP2281568A2 Uses of soluble CTLA4 mutant molecules |
| 02/09/2011 | EP2281004A1 Prostate specific membrane antigen antibodies and antigen binding fragments |
| 02/09/2011 | EP2281002A2 Anti-alk1 antibodies and uses thereof |
| 02/09/2011 | EP2281001A1 Anti-areg/hb-egf antibodies and treatment |
| 02/09/2011 | EP2280994A1 Restoration of estrogen receptor-alpha activity |
| 02/09/2011 | EP2280985A2 Use of mannose-6-phosphate for controlling angiogenesis, ligament regeneration, and cartilage reconstruction |
| 02/09/2011 | EP2280983A2 C-aryl glycoside compounds for the treatment of diabetes and obesity |
| 02/09/2011 | EP2280982A1 Thiazolyl-dihydro-indazoles |
| 02/09/2011 | EP2280962A1 Pyridazinone derivatives |
| 02/09/2011 | EP2280952A1 Thienopyridone derivatives as amp-activated protein kinase (ampk) activators |
| 02/09/2011 | EP2280946A1 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases |
| 02/09/2011 | EP2280940A1 Novel n-(2-amino-phenyl)-acrylamides |
| 02/09/2011 | EP2280915A1 Novel ýf-18¨-labelled l-glutamic acid and l-glutamine derivatives (ii), use thereof and method for their production |
| 02/09/2011 | EP2280742A2 Medical devices, polymers, compositions, and methods for delivering a haloacetate |
| 02/09/2011 | EP2280699A1 Novel estrogen receptor ligands |
| 02/09/2011 | EP2280693A2 Liquid and freeze dried formulations |
| 02/09/2011 | EP2033637B1 Therapeutic or prophylactic agent for leukemia |
| 02/09/2011 | EP1819227B1 Pharmaceutical formulation of decitabine |
| 02/09/2011 | EP1575955B1 Pyrrolobenzodiazepines for the treatment of proliferative diseases |
| 02/09/2011 | EP1451192B1 Novel crystalline compound |
| 02/09/2011 | EP1379508B9 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof |
| 02/09/2011 | EP1370276B1 Intercellular communication facilitating compounds and their medical use |
| 02/09/2011 | EP0668777B2 Prostate-specific membrane antigen |
| 02/09/2011 | CN1889950B The use of urocanic acid being able to acidify the cell cytoplasm and for preventing or halting cellular proliferation in a person |
| 02/09/2011 | CN1882602B The modulation of hyaluronan synthesis and degradation in the treatment of disease |
| 02/09/2011 | CN1816563B Polypeptides having binding affinity for HER2 |
| 02/09/2011 | CN1547464B Prolonged release bioadhesive therapeutic systems |
| 02/09/2011 | CN101970670A Methods for inhibiting angiogenesis using egfl8 antagonists |
| 02/09/2011 | CN101970500A Anti-tyrp1 antibodies |
| 02/09/2011 | CN101970496A Antibody against the csf-1 r |
| 02/09/2011 | CN101970489A Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same |
| 02/09/2011 | CN101970485A Heparin-binding epidermal growth factor-like growth factor antigen binding proteins |
| 02/09/2011 | CN101970457A Inhibitors of iap |
| 02/09/2011 | CN101970442A Bicyclic pyrrole compound |
| 02/09/2011 | CN101970440A 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| 02/09/2011 | CN101970426A Indazolyl, benzimidazolyl, benzotriazolyl substituted indolmone derivatives as kinase inhibitors useful in the treatment of cancer |
| 02/09/2011 | CN101970425A Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts |
| 02/09/2011 | CN101970424A Indolyl- pyridone derivatives having checkpoint kinase 1 inhibitory activity |
| 02/09/2011 | CN101970418A Novel compounds, use and preparation thereof |